Premium
Systems Approaches in Risk Assessment
Author(s) -
Lesko L J,
Zheng S,
Schmidt S
Publication year - 2013
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2013.29
Subject(s) - clinical pharmacology , observational study , personalized medicine , risk analysis (engineering) , identification (biology) , systems biology , complement (music) , systems pharmacology , risk assessment , drug development , health care , precision medicine , clinical practice , computer science , data science , drug , medicine , bioinformatics , pharmacology , biology , pathology , political science , biochemistry , botany , computer security , complementation , gene , phenotype , family medicine , law
Adverse drug events (ADEs) remain a universal problem in drug development, regulatory review, and clinical practice with a substantial financial burden on the global health‐care system. Recent advances in molecular and “omics” technologies, along with online databases and bioinformatics, have enabled a more integrative approach to understanding drug‐target (protein) interactions, both desirable and undesirable, within a biological system. This has led to the development of systems approaches to risk assessment in an attempt to complement and improve on contemporary observational and predictive strategies for assessing risk. Although still in an evolutionary phase, systems approaches have the potential to markedly advance our understanding of ADEs and ability to predict them. Systems approaches will also move personalized medicine forward by enabling better identification of individual and subgroup risk factors. Clinical Pharmacology & Therapeutics (2013); 93 5, 413–424. doi: 10.1038/clpt.2013.29